Yukari Okubo

Shinjuku, 1608402, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 142 publications

Regulation of Imiquimod-Induced Mouse Psoriasis Development via Apoptosis Signal-Regulating Kinase 1 Potentially by Antagonizing Aryl Hydrocarbon Receptor Expression.

Regulation of Imiquimod-Induced Mouse Psoriasis Development via Apoptosis Signal-Regulating Kinase 1 Potentially by Antagonizing Aryl Hydrocarbon Receptor Expression.

Journal: Current issues in molecular biology

Published: May 25, 2026

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.

Journal: The Journal of dermatology

Published: April 28, 2026

Intravenous Tranexamic Acid-Induced Anaphylaxis.

Intravenous Tranexamic Acid-Induced Anaphylaxis.

Journal: The Journal of dermatology

Published: January 16, 2026

Treatment Guidance for Palmoplantar Pustulosis 2022.

Treatment Guidance for Palmoplantar Pustulosis 2022.

Journal: The Journal of dermatology

Published: November 04, 2025

Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial.

Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial.

Journal: Dermatology and therapy

Published: October 01, 2025

An Exploratory Study to Identify Factors Associated with Recurrence of Generalized Pustular Psoriasis Flares in Adult Patients in Japan.

An Exploratory Study to Identify Factors Associated with Recurrence of Generalized Pustular Psoriasis Flares in Adult Patients in Japan.

Journal: Acta dermato-venereologica

Published: September 10, 2025

Prospective, Open-Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics.

Prospective, Open-Label, Multicenter Study of Apremilast as Maintenance Therapy for Psoriasis Patients in Remission With Biologics.

Journal: The Journal of dermatology

Published: August 05, 2025

Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study.

Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study.

Journal: Dermatology and therapy

Published: May 15, 2025

Intralesional Carmellose Sodium Injection-Induced Urticaria.

Intralesional Carmellose Sodium Injection-Induced Urticaria.

Journal: The Journal of dermatology

Published: April 30, 2025

Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With Biologics.

Questionnaire Survey on the Treatment of Psoriasis Patients Who Achieved Remission With Biologics.

Journal: The Journal of dermatology

Published: April 03, 2025

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 14, 2025

Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study.

Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study.

Journal: The Journal of dermatology

Published: February 14, 2025

Showing 1-12 of 142

Last Updated: 09/26/2026